Financial Statement

Fiscal Year Ends	:	December
( in million Rupiah except Par Value, Per Share Data and Ratios )
Statement Date	:	2024-03-31
Balance Sheet
Cash & Cash Equivalents	:	822,088
Curr. Assets	:	4,601,501
Fixed Assets	:	9,682,181
Total Assets	:	14,283,682
Curr. Liabilities	:	4,063,489
Long Term Debt	:	3,829,285
Minority Interest	:	0
Total Liabilities	:	7,892,774
Paid-Up Capital	:	10,366
Total Equity	:	6,390,908
Income Statement
Total Sales	:	710,869
Gross Profit	:	210,297
Operating Profit	:	22,395
Net Income	:	-61,745
Cash Flow Statement
Cash From Operating Act	:	-47,836
Cash From Investing Act	:	-41,591
Cash From Financing Act	:	-43,182
Per Share Data (in IDR)
EPS	:	-5.96
Book Value	:	616.53
Financial Ratios
Der	:	1.24
Roa	:	-0.35
Roe	:	-0.04
Npm	:	-0.09
Opm	:	0.03
Growth Year to Year
Sales (%)	:	100.00%
Net Income (%)	:	100.00%
Total Assets (%) (%)	:	100.00%
Total Liabilities (%)	:	100.00%

1	RAK ICC Provides Strategic Solutions for Holding Companies and Regional Expansion

2	Illumina and PREMIA partner to expand clinical access to CGP in Asia

3	Rokid and Ant International Announce Integration of Smart Glasses Payment Capability

4	Salcomp's Debut on CES 2026

5	Call for Application for 2026 Tsinghua Amgen Scholars Program

RAK ICC Provides Strategic Solutions for Holding Companies and Regional Expansion